{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:10:51Z","timestamp":1787962251928,"version":"build-2784847793"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Recent studies point toward a potential benefit of doxycycline use for post-exposure prophylaxis (PEP) or pre-exposure prophylaxis (PrEP) to prevent sexually transmitted infections (STIs). Although prescribing doxycycline in a prophylactic intention is not generally recommended yet, we noticed an increasing number of inquiries from individuals within the LGBTQ community for doxycycline prescriptions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted an anonymous online survey to evaluate the current extent of doxycycline use for PEP or PrEP within the LGBTQ community using REDCap electronic data capture tools. Participants gained access to the online survey through a QR code on posters in the premises of our STI outpatient department and at LGBTQ community-related events in the south-western region of Germany. Additional access was provided by a direct link shared on social media profiles for men having sex with men (MSM), transgender, and queers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>96 of 99 responses were eligible for analysis. Twenty-two participants (23%) indicated to have already used doxycycline for PEP and six participants (6%) used doxycycline for PrEP. The majority of participants used pills left over from previous doxycycline treatment. Forty percent of indicated modes of access were without a regular prescription, e.g., by provision from acquaintances (with or without healthcare profession) or by ordering online.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our study shows that the concept of doxycycline use for prevention of STIs is already well known and applied in the LGBTQ community. Further analysis, especially modeling studies, are needed to evaluate strategies aiming to reduce doxycycline intake (PEP\/PrEP versus repeated targeted therapies) and improve sexual health outcomes within the community.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s15010-023-02086-9","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T16:01:45Z","timestamp":1692720105000},"page":"1831-1834","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Already current practice? A snapshot survey on doxycycline use for prevention of sexually transmitted infections in parts of the German MSM community"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-3341","authenticated-orcid":false,"given":"Daniel","family":"Hornuss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Math\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Usadel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegbert","family":"Rieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,22]]},"reference":[{"key":"2086_CR1","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/OLQ.0000000000000216","volume":"42","author":"RK Bolan","year":"2015","unstructured":"Bolan RK, Beymer MR, Weiss RE, Flynn RP, Leibowitz AA, Klausner JD. Doxycycline prophylaxis to reduce incident syphilis among HIV-infected men who have sex with men who continue to engage in high-risk sex: a randomized. Controlled Pilot Study Sex Transm Dis. 2015;42:98\u2013103.","journal-title":"Controlled Pilot Study Sex Transm Dis"},{"key":"2086_CR2","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/S1473-3099(17)30725-9","volume":"18","author":"JM Molina","year":"2018","unstructured":"Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis. 2018;18:308\u201317.","journal-title":"Lancet Infect Dis"},{"key":"2086_CR3","unstructured":"Jean-Michel Molina\u2014HIV AND STI PREVENTION: NEW TOOLS AND APPROACHES\u2014CROI 2023 [Internet]. https:\/\/www.croiwebcasts.org\/console\/player\/51576?mediaType=slideVideo&. Accessed 18 May 2023."},{"key":"2086_CR4","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa2211934","volume":"388","author":"AF Luetkemeyer","year":"2023","unstructured":"Luetkemeyer AF, Donnell D, Dombrowski JC, Cohen S, Grabow C, Brown CE, et al. Postexposure doxycycline to prevent bacterial sexually transmitted infections. N Engl J Med. 2023;388:1296\u2013306.","journal-title":"N Engl J Med"},{"key":"2086_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1071\/SH23011","volume":"20","author":"VJ Cornelisse","year":"2023","unstructured":"Cornelisse VJ, Ong JJ, Ryder N, Ooi C, Wong A, Kenchington P, et al. Interim position statement on doxycycline post-exposure prophylaxis (Doxy-PEP) for the prevention of bacterial sexually transmissible infections in Australia and Aotearoa New Zealand\u2014the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM). Sex Health. 2023;20:99\u2013104.","journal-title":"Sex Health"},{"key":"2086_CR6","unstructured":"Werner RN, Schmidt AJ, Potthoff A, Spornraft-Ragaller P, Brockmeyer NH. Antibiotische STI-Prophylaxe mit Doxycyclin (\u201eDoxy-PEP\u201c, \u201eDoxy-PrEP\u201c). https:\/\/www.dstig.de\/wp-content\/uploads\/2023\/07\/Stellungnahme_STI-Prophylaxe.pdf"},{"key":"2086_CR7","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1186\/s12889-022-14323-1","volume":"22","author":"X Zhang","year":"2022","unstructured":"Zhang X, Qi SZ, Du FZ, Zheng ZJ, Cao NX, Zheng XL, et al. Awareness and willingness to accept syphilis chemoprophylaxis among men who have sex with men from three cities in China: a cross-sectional study. BMC Public Health. 2022;22:1926.","journal-title":"BMC Public Health"},{"key":"2086_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95: 103208.","journal-title":"J Biomed Inform"},{"key":"2086_CR9","unstructured":"Franklin CH. The \u2018Margin of Error\u2019 for Differences in Polls. https:\/\/abcnews.go.com\/images\/PollingUnit\/MOEFranklin.pdf"},{"key":"2086_CR10","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/S1473-3099(20)30154-7","volume":"20","author":"DA Machalek","year":"2020","unstructured":"Machalek DA, Tao Y, Shilling H, Jensen JS, Unemo M, Murray G, et al. Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis. Lancet Infect Dis. 2020;20:1302\u201314.","journal-title":"Lancet Infect Dis"},{"key":"2086_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106510","volume":"59","author":"SS Lee","year":"2022","unstructured":"Lee SS, Cheng KF, Wong NS, Kwan CK, Lau OC, Cheng HF, et al. Emergence of antibiotic-resistant Mycoplasma genitalium as the cause of non-gonococcal urethritis in male patients at a sexually transmitted infection clinic. Int J Antimicrob Agents. 2022;59: 106510.","journal-title":"Int J Antimicrob Agents"},{"key":"2086_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2022.102403","volume":"49","author":"A Kantele","year":"2022","unstructured":"Kantele A, Mero S, L\u00e4\u00e4veri T. Doxycycline as an antimalarial: impact on travellers\u2019 diarrhoea and doxycycline resistance among various stool bacteria\u2014prospective study and literature review. Travel Med Infect Dis. 2022;49: 102403.","journal-title":"Travel Med Infect Dis"},{"key":"2086_CR13","unstructured":"Whiley DM, Tickner JA, Kundu RL, Hogan TR, Hal SJ van, Lahra MM. Selection of Neisseria gonorrhoeae ceftriaxone resistance using doxycycline post-exposure prophylaxis. Lancet Infect Dis [Internet]. 2023;0. https:\/\/www.thelancet.com\/journals\/laninf\/article\/PIIS1473-3099(23)00359-6\/fulltext. Accessed 14 Jun 2023."}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-023-02086-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-023-02086-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-023-02086-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T11:07:02Z","timestamp":1700651222000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-023-02086-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,22]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2086"],"URL":"https:\/\/doi.org\/10.1007\/s15010-023-02086-9","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,22]]},"assertion":[{"value":"27 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DH reports personal fees from Akademie f\u00fcr Infektionsmedizin e.V. and bioM\u00e9rieux SA. PM reports personal fees from bioM\u00e9rieux SA. SU reports personal fees from Gilead Sciences, MSD, and ViiV Health Care. SR reports personal fees from Pfizer, Med Update GmbH, Falk Foundation, bioM\u00e9rieux SA, Med Update GmbH, stremedup! GmbH, and Deutscher Apotheker-Verlag. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"In accordance with the regulations of the local ethics\u2019 review board (Ethik-Kommission der Albert-Ludwigs-Universit\u00e4t Freiburg), informed consent was not obtained due to the voluntary provision of complete anonymized data by the participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}